|
CONNETICUT
New
Haven
 CuraGen
combines genomics expertise with integrated, industrialized technologies
to rapidly discover genes, ascertain their function, and categorize
them as potential protein drugs, antibody targets, and small molecule
drug targets. Scientists and engineers at CuraGen have developed
a suite of integrated functional genomic technologies and have combined
these with comprehensive disease programs to gain an in-depth understanding
of how genes and their related proteins function in the context
of disease.
|
|
Gerstein
Lab (Yale)
Center
for Structural Biology
(Yale)
MAINE
|
|
MASSACHUSETTS
Beverly
 Bought
by Incyte Genomics. Proteome, Inc. is dedicated to reducing the
complexity of the information landscape by providing researchers
in the life science industry with an integrated biological knowledge
system that combines experimental protein knowledge captured by
comprehensive human curation, the latest genomic and functional
genomic datasets, and powerful software tools to reveal the connectivity
of biological knowledge across the species.
|
|
Billerica
 A
global company focused on the advancement of all of the sciences
supported by mass spectrometry, with a commitment to finding new
and more powerful uses of MS technology wherever possible. Supplies
the PROTEUM Series of products which is focused on the determination
of crystallographic structures of proteins and other biological
macromolecules. Don't forget, Bruker
Daltonik Germany has a terrific website.
|
|
Boston/Cambridge
 ProteinScience.com
was established in March 2000 with the goal of being the preeminent
news and information web portal devoted to proteomics and protein
science.
info@proteinscience.com
|
|
BioMolecular
Engineering Research Center (Boston U)
Ellenburger
Lab (Harvard)
Harvard
Medical School Institute of Proteomics
Harvard
Microchemistry and Proteomics Analysis Facility
Harvard
Structural Genomics of Cancer Initiative
Hogle
Lab (Harvard)
Gygi
Lab (Harvard)
Lipper
Center for Computational Genetics (Harvard)
|
Vertex's information-driven drug design approach combines diverse
technology disciplines and an integrated organizational philosophy
to increase the speed and success rate of drug discovery and development.
The information-driven drug design approach is dynamic-it has incorporated
and continues to integrate new technologies within the framework of
core biology, chemistry and biophysics disciplines. Vertex has developed
a variety of advanced and proprietary approaches, including compound
screening using NMR SHAPES, virtual screening using computer modeling
and combinatorial chemistry, and early incorporation of pharmacological
testing to drive the drug discovery process. By using these approaches,
as well as a range of available technologies, including use of x-ray
crystallography to determine the three-dimensional structure of a
drug target, Vertex has been able to accelerate drug discovery timelines
and increase success rates in early development compared to industry
averages. |
| Wagner
Lab (Harvard) |
|
Framingham
 Applied
Biosystems announced the formation of a center for proteomics research
at its PerSeptive Biosystems Division. The Proteomics Research Center's
mission is to define novel tools for proteomics, focus on the advancement
of the science of proteomics, and develop practical application-based
systems for the fields of research, drug discovery and development,
and health care.
|
|
Hopkinton
HTS Biosystems' Proteomatrix™ Solution requires a number of
different technologies. HTS Biosystems has assembled an impressive
combination of proprietary technologies to allow us to offer the
best tools to meet the specific needs of different segments of the
proteomics market. The solutions we provide for our customers are
targeted to their needs and not limited by our technology portfolio.
|
|
Lexington
 Phylos
is leading the development of an integrated drug discovery program
based on its powerful combinatorial biology platform, PROfusion™
technology. The platform is being broadly applied to the high throughput
discovery of high affinity and highly specific binding proteins
for research, microarray, and biotherapeutic applications.
|
|
Newton
 Matritech
is a leading developer of proteomics-based diagnostic products for
the early detection of cancer. Using its patented proteomics technology,
Matritech has identified proteins correlated with breast, bladder,
prostate, cervical and colon cancers. Matritech is one of the first
companies to successfully employ proteomics to create diagnostic
products. The company holds one of only two FDA product approvals
for the initial detection of cancer. The FDA-approved NMP22 bladder
cancer test is currently used by urologists. In addition, the company
has a promising blood-based breast cancer test, NMP66, in clinical
trials. Initial research on a prostate cancer marker identified
by Matritech scientists shows the maker to be more accurate than
the widely-used PSA test. NMP technology was licensed exclusively
to Matritech from the Massachusetts Institute of Technology.
|
|
Woburn
 Proteome
Systems is dedicated to the development of proteomics technology,
to the discovery of biomarkers and drug targets, and to proteomic
bioinformatics. Established in 1999, Proteome Systems has quickly
grown to become one of the world's major forces in proteomics. Proteome
Systems is headquartered in Sydney, Australia and has premises in
the Boston area in the United States. Both sites have more than
20,000 square feet of office and/or laboratory space. With over
70 staff, more than half which hold PhDs, Proteome Systems has developed
an integrated suite of novel technology to make the world's first
integrated, high-throughput platform for proteome analysis. This
platform, ProteomIQ™ currently deployed on a large scale in
the Sydney laboratories and soon to be deployed in many sites around
the world, is massively accelerating Proteome Systems' discovery
research. Proteome Systems Ltd is an Australian private company.
Its shareholders include its founders, senior management and other
private corporations.
|
|
Waltham
 Beyond
Genomics (BG) is revolutionizing drug discovery with a novel Systems
Biology approach. The BG approach literally goes 'beyond genomics'
to analyze complex clinical samples at a biological systems level.
More specifically, we analyze and integrate data at the gene/transcript,
protein and metabolite levels using our proprietary BioSystematics™;
technology. The resulting systems biology information allows BG
to create knowledge that advances pharmaceutical R & D by providing
new insights into the molecular mechanisms of health and disease.
Our discovery efforts focus on applying this knowledge to the development
and discovery of novel therapeutics to treat human disease. Our
technologies and unique approach are applied throughout the drug
discovery and development process. The broad utility of BG's approach
allows us to leverage our capabilities; transcriptomics/genomics,
proteomics and metabolomics, across a portfolio of applications.
BG's BioSystem Marker™; identification enables us to bridge
the pharmaceutical innovation gap by uncovering new pathways for
therapeutics-filling pipeline shortfalls and meeting unmet medical
needs. Beyond Genomics was founded in November 2000 by thought leaders
in systems biology from Harvard, Purdue, Indiana, and Leiden (The
Netherlands) Universities. We currently operate labs and occupy
office space in Waltham, MA, and support researchers in The Netherlands.
|
|
 GPC
Biotech AG is a leading transatlantic genomics-driven drug discovery
company with a broad integrated technology platform that is unparalleled
in Europe. A number of proprietary genomics, proteomics and drug
discovery technologies help to accelerate the process of drug discovery
and development. Alliances with leading global pharmaceutical companies
validate GPC Biotech's technologies and generate revenue streams
that help fund the Company's internal drug discovery projects which
are focused on oncology, infectious diseases and immunology. GPC
Biotech has a broad intellectual property position. In March 2000,
the acquisition of the drug discovery company Mitotix, Inc. (now
GPC Biotech Inc., Waltham/USA), which has world-leading expertise
in cell cycle research, significantly accelerated the Company's
forward integration. The combined Company realizes a common and
powerful vision of integrated genomics- and proteomics-based drug
discovery throughout the entire process of drug discovery, from
target discovery to the clinic.
|
|
NEW
HAMPSHIRE
RHODE
ISLAND
VERMONT
|
|
|
|
